Compugen autoimmune, cancer news

Compugen said its annual R&D cash expenditure will increase to more than $16 million this year from about $10 million in 2013 to allow for research and preclinical activities for a larger number of checkpoint target inhibitors and cancer immunotherapy targets. The company also aims to establish a biomarker discovery program for checkpoint product candidates and to accelerate experimental validation for antibody-drug conjugate (ADC) therapies. As part of the expansion, Compugen said it will relocate its U.S. R&D subsidiary to larger facilities in South San Francisco in mid-2014. ...